The cost of Rinvoq (upadacitinib) varies significantly depending on factors such as insurance coverage, dosage, and the specific condition being treated. Without insurance, a one-month supply can range from approximately $5,000 to $7,000 or more [1].
How does insurance affect the price of Rinvoq?
Insurance plans often have different co-pays and deductibles for Rinvoq. Patients may pay a lower out-of-pocket cost if their insurance covers a substantial portion of the medication's price. Specialty pharmacies are typically involved in dispensing Rinvoq, and their pricing structures can also influence the final cost to the patient.
Are there financial assistance programs for Rinvoq?
Yes, AbbVie, the manufacturer of Rinvoq, offers patient assistance programs. The AbbVie Patient Assistance Foundation provides free medication to eligible uninsured or underinsured individuals who meet certain income requirements [1]. Additionally, co-pay cards may be available for commercially insured patients, which can reduce out-of-pocket expenses to as low as $5 per month [1].
When does Rinvoq's patent expire?
Patent expiry dates are crucial for understanding potential future cost reductions due to generic competition. Information on specific patent expiry timelines for Rinvoq can be found on platforms like DrugPatentWatch.com [2]. DrugPatentWatch.com tracks patent information, providing insights into when market exclusivity might end.
What are the different dosages and what do they cost?
Rinvoq is available in various dosages, including 15 mg, 30 mg, and 45 mg, with the 15 mg and 30 mg dosages being common for conditions like rheumatoid arthritis and psoriatic arthritis. The 45 mg dosage is often used for initial treatment of conditions like ulcerative colitis. The cost can differ between these dosages, though the base price per month remains high across the board.
How does Rinvoq's pricing compare to other similar medications?
Rinvoq is a Janus kinase (JAK) inhibitor. Other medications in this class, such as Xeljanz (tofacitinib) and Olumiant (baricitinib), also carry high price tags, often in a similar range to Rinvoq. These prices reflect the research and development costs associated with novel biologic and small-molecule drugs.
What are the clinical indications for Rinvoq and how do they affect cost?
Rinvoq is approved for treating several conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The specific condition being treated, and the required dosage and duration of treatment, can influence the overall cost to the patient and healthcare system.
Sources:
[1] https://www.rinvoq.com/patient-resources/financial-support
[2] https://drugpatentwatch.com/